Compare Ginkgo Bioworks Holdings Inc (DNA) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs UiPath Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.99 (market cap $772.39M), while UiPath Inc trades at $13.3 (market cap $6.81B). The key difference: UiPath Inc is far larger — about 8.8× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and UiPath Inc for 139 Days on average.
| DNA | PATH | |
|---|---|---|
Market Cap | $772.39M | $6.81B |
Volume | 6,453,273 | 22,766,109 |
Sector | Health | Technology |
52-Week High | $15.83 | $19.29 |
52-Week Low | $5.48 | $9.38 |
Typical Hold Time | 7 Days | 139 Days |
Enterprise Value | $874.34M | $5.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
UiPath (PATH) trades at $13.07, down 0.23% on the day, amid a bearish technical signal and mixed earnings history. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while net income is expected to turn positive. Recent news highlights AI partnerships and product innovations, but the stock faces headwinds from cautious analyst sentiment and technical resistance.
The outlook for PATH is cautiously optimistic, with strong revenue growth and a path to profitability offering upside potential, but risks include execution challenges and competitive pressures. The consensus price target of $15.13 suggests moderate upside from current levels, though investor sentiment remains divided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
